關(guān)鍵詞： 阿斯利康 無機(jī)控釋
2013年1月23日訊 /生物谷BIOON/ --阿斯利康（AstraZeneca）周二宣布，與國際材料開發(fā)公司Ceram Research公司簽署了一份協(xié)議,。根據(jù)協(xié)議條款,，Ceram將在一項(xiàng)可行性研究中開發(fā)其無機(jī)控釋技術(shù),，用于遞送阿斯利康所挑選的化合物,。這項(xiàng)技術(shù)如果成功實(shí)施,，將為阿斯利康提供一種可供選擇的配方方法來遞送這些化合物,。（生物谷bioon.com）
英文原文：AstraZeneca inks pact with Ceram Research to develop inorganic-based controlled release technology
London Tuesday, January 22, 2013, 17:00 Hrs [IST]
AstraZeneca, a global pharmaceutical company, has signed an agreement with the international materials development company, Ceram Research Ltd. Under the terms of aggreement Ceram will develop its inorganic-based controlled release technology in a feasibility study for the delivery of selected AstraZeneca compounds.
“This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds,” said Tony Kinsella, CEO, Ceram.
Controlled release technology is just one of the development projects that Ceram’s team of materials experts is currently working on; others include multi-element substituted hydroxyapatite for orthopaedic device coating applications.
With Healthcare as one of its largest markets, the materials development business has ambitious plans to continue its growth in the US and Europe.
Tony Kinsella further informed, “Our work is focussed on commercial development of materials for industrial applications - exactly what a recent news item on the BBC said was lacking in Britain. We have, for example, recently helped Greatbatch Medical to gain FDA (510K) approval of a coating implant submission. We have also worked with GlaxoSmithKline in the proving of its Sensodyne toothpaste - a product that has seen substantial annual growth over the last decade, creating significant incomes for both GSK and the UK.”
